

# CORPORATE SOCIAL RESPONSIBILITY NEWS TODAY

Tuesday, June 7, 2016

[GET RSS FEED](#)
[SUBMIT RELEASE](#)

articles: 329,717,428

readers: 3,848,365

**The Media Is in Error When They Lumped Superdelegates With Pledged Delegates...**

**EIN PRESSWIRE**

Reach over 5,000,000 people with one click

[LEARN MORE ▶](#)

[Submit a press release](#) · [See all](#)

**EIN NEWSFEED MAKER**

Get Professional-Quality News Delivered to Your Website or Blog 24 Hours a Day



## Got News to Share?

Send 2 FREE Releases



[Menu](#) > [All News Topics](#) > [Corporate Social Responsibility News Topics: By Country | By State](#) ; [Press Releases by Industry Channel](#) > [All Corporate Social Responsibility Press Releases](#)

**EIN PRESSWIRE**

## MedGenome partners with ZellNet Consulting to offer powerful genomics solutions in immune-oncology research

*ZellNet will be a distributor for MedGenome's OncoPept™ – a powerful end to end genomics platform to accelerate immune-oncology research.*

FOSTER CITY, CA, UNITED STATES, June 4, 2016 /EINPresswire.com/ – MedGenome announced a strategic partnership with ZellNet Consulting – a trusted provider of immune monitoring services for over 18 years.

This arrangement seamlessly integrates MedGenome's [cancer immunotherapy genomics platform](#) with ZellNet's immune monitoring services. This partnership will facilitate present customers of ZellNet's immune monitoring services to quickly expand their cancer immunotherapy research into the genomics space by leveraging the power of next-generation sequencing-based approaches of neo-antigen and neo-epitope prediction. Additionally, they will have the option to interrogate the [tumor microenvironment](#) to understand the immune cell content, cytokine network and pro-inflammatory or immune-suppressive pathways in the tumor. The OncoPept platform offered through ZellNet will enhance their current service offerings with upstream genomics to serve the customer base of both MedGenome and ZellNet.

"ZellNet is excited about the opportunity to expand its offered services with MedGenome's cutting-edge OncoPept™ platform, a logical and timely extension" says Sylvia Janetzki, President, ZellNet Consulting "The partnership allows us to integrate important steps within the translational research and vaccine development pipeline: from what to monitor to how to monitor. Customers can continue relying on ZellNet's superior service standards. We are proud to partner with such an exceptional company as MedGenome, and look forward to passing the advantages of this high value addition to our customers"

MedGenome is the only Next Generation Sequencing (NGS) service provider offering immune oncology researchers an enduring science-driven partnership to deliver quicker, more affordable, customized solutions to achieve superior therapeutic impact of checkpoint control inhibitors and cancer vaccines through its cancer immunotherapy genomics platform, OncoPept™.

